NASDAQ : OKUR

OnKure Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 2.62 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 106.10M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.

Details

NameOnKure Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees45
Founded2011
CeoNicholas Saccomano
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS68277Q1058
Cusip68277Q105
Cik0001637715
Sic2834
Stock TypeCommon Stock
Share ClassClass A Shares

Key executives

NameTitle
Dr. Nicholas A. Saccomano Ph.D.President, Chief Executive Officer and Director
Jason A. Leverone CPAChief Financial Officer
Dr. Isaac Manke Ph.D.Senior Vice President of Business Development and Director
Dr. Samuel Agresta M.D., M.P.H.Chief Medical Officer
Dr. Dylan Hartley Ph.D.Chief Scientific Officer
Rogan P. Nunn J.D.General Counsel and Secretary
Dr. James Blake Ph.D.Senior Vice President of Computational Drug Discovery
Dr. Kevin S. Litwiler Ph.D.Senior Vice President of DMPK and Clinical Pharmacology
Dr. Mark L. Boys Ph.D.Senior Vice President of Discovery Chemistry
Roberta AltonSenior Vice President of Clinical Operations

Contact

Address6707 Winchester Circle, Suite 400, Boulder, Colorado 80301, United States
Phone720-307-2892
Websitehttps://onkuretherapeutics.com